PharmaResearch announced on the 29th that it has signed a partnership agreement with the French aesthetic corporation VIVACY to fully launch the medical device 'Rejuran' into the European market. The scale of the contract is 88 billion won over five years.
Based in France, VIVACY is a leading corporation in the European medical aesthetic field and has subsidiaries and branches in major metropolitan cities.
PharmaResearch stated that it plans to accelerate its strategy to penetrate the European market by combining VIVACY's distribution and marketing capabilities with the aesthetic expertise of 'Rejuran'. The goal is to enter into strategic markets across 22 countries, including major Western European nations such as the UK, Germany, France, Italy, and Spain. The company noted, "We aim to start supply primarily in Western European countries within this year and gradually expand across Europe."
Son Ji-hoon, CEO of PharmaResearch, said, "Rejuran is the only brand among PN (Polynucleotide) component medical devices to have received approval under the European Medical Device Regulation (MDR), meeting stringent safety and efficacy standards, so we expect to gain a distinct competitive advantage." He added, "We will widely promote Rejuran to consumers globally and solidify its position as a leading global skin booster."
Bertrand Proly, CEO of VIVACY, said, "I am confident that we will successfully launch Rejuran in the European market," and noted, "This partnership will serve as a significant turning point in establishing new standards in the field of skin regeneration in Europe."